Regeneron And Sanofi's Dupixent Approved In Japan As First Targeted Medicine For Adults With Moderate-To-Severe Bullous Pemphigoid - Regeneron Pharmaceuticals (NASDAQ:REGN), Sanofi (NASDAQ:SNY)
Published on March 24, 2026.
The first time two companies have been approved for the treatment of adults with moderate-to-severe Pemphigoid, is set to be the first time in Japan. The drug is also being used as a treatment for other patients. The company's Dupixent has been approved by both the government and the pharmaceutical industry.
Related Articles
D CEO Commercial Real Estate Awards 2026
The 2026 D. uniquely titled "Ethic" is the name of the event, with notable contributions from both sides of the Atlantic, including:
Fans fear 'asset strip' takeover bid at Featherstone Rovers - councillor
Featherstone councillor Scott Haslam expressed concern over a potential "asset strip" takeover of the club, with bids until September due.
As Mass Adoption Approaches, Crypto Has Forgotten Its Roots
As crypto adoption rapidly increases, decentralized finance is rapidly evolving into a framework of surveillance and governance tools that prioritize individual freedom and governance rather than centralized control.